OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and outcomes.
OmniSeq Insight is a solid tumor test that combines genomic and immune profiling with immune gene expression data, according to the firm. Users receive test results in a report that includes a summary of U.S. Food and Drug Administration-approved therapies that match the tumor profile; they also receive recommendations for treatment based on information from a proprietary database that includes National Comprehensive Cancer Network (NCCN) guidelines.
OmniSeq is offering the test in the U.S. through Labcorp and in Canada through Dynacare, a Labcorp subsidiary, it said.
